Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.11 USD | -0.16% | -5.70% | +26.12% |
Financials (USD)
Sales 2024 * | 51.54M | Sales 2025 * | 72.35M | Capitalization | 1.97B |
---|---|---|---|---|---|
Net income 2024 * | -205M | Net income 2025 * | -237M | EV / Sales 2024 * | 30.9 x |
Net cash position 2024 * | 380M | Net cash position 2025 * | 373M | EV / Sales 2025 * | 22.1 x |
P/E ratio 2024 * |
-11.2
x | P/E ratio 2025 * |
-9.98
x | Employees | 186 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
Latest transcript on Kymera Therapeutics, Inc.
1 day | -0.16% | ||
1 week | -5.70% | ||
1 month | -11.54% | ||
3 months | -26.18% | ||
6 months | +54.60% | ||
Current year | +26.12% |
Managers | Title | Age | Since |
---|---|---|---|
Nello Mainolfi
FOU | Founder | 45 | 15-08-31 |
Bruce Jacobs
DFI | Director of Finance/CFO | 54 | 19-07-14 |
Juliet Williams
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | Mar. 27 |
Joanna Horobin
BRD | Director/Board Member | 69 | 18-04-30 |
John Maraganore
BRD | Director/Board Member | 60 | 22-01-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.05% | 1,487 M€ | +7.77% | - | |
0.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 32.11 | -0.16% | 537,348 |
24-05-30 | 32.16 | -1.02% | 604,436 |
24-05-29 | 32.49 | -3.10% | 402,854 |
24-05-28 | 33.53 | -1.53% | 481,896 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.12% | 1.97B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- KYMR Stock